SEARCH

SEARCH BY CITATION

References

  • 1
    Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 17251730.
  • 2
    Correll PK, Law MG, McDonald AM, Cooper DA, Kaldor JM. HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust 1998; 169: 469472.
  • 3
    Hogg RS, Heath KV, Yip B et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. J Am Med Assoc 1998; 279: 450454.
  • 4
    Law MG, Li Y, McDonald AM, Cooper DA, Kaldor JM. Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection. AIDS 2000; 14: 197201.
  • 5
    Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. Br Med J 1997; 315: 11941199.
  • 6
    Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853860.
  • 7
    Cohen J. AIDS treatment. A step toward cheaper anti-HIV therapy. Science 2005; 307: 653.
  • 8
    Kapczynski A, Crone ET, Merson M. Global health and university patents. Science 2003; 301: 1629.
  • 9
    Dyer O. New 20 year patents threaten to end AIDS drugs for developing countries. Br Med J 2004; 329: 1308.
  • 10
    Eggertson L. Cheaper HIV/AIDS drugs coming. Can Med Assoc J 2004; 170: 1905.
  • 11
    Eggertson L. Martin government to reintroduce patent changes. Cmaj 2004; 170: 456.
  • 12
    Elliott R. TRIPS from Doha to Cancun … to Ottawa: global developments in access to treatment and Canada's Bill C-56. Can HIV AIDS Policy Law Rev 2003; 8: 718.
  • 13
    Spurgeon D. Canada decides to lead the way in exempting AIDS drugs from patent laws. Br Med J 2003; 327: 832.
  • 14
    Rassool GH. WHO and UNAIDS unveil plans for 3 by 5 AIDS programme. J Adv Nurs 2004; 46: 567569.
  • 15
    Yeni PG, Hammer SM, Carpenter CC et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 2002; 288: 222235.
  • 16
    Carpenter CC, Cooper DA, Fischl MA et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 2000; 283: 381390.
  • 17
    Arici C, Ripamonti D, Ravasio V et al. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution. Int J STD AIDS 2001; 12: 573581.
  • 18
    Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002; 16: 201207.
  • 19
    Dragsted UB, Mocroft A, Vella S et al. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis 2004; 190: 148155.
  • 20
    Hunt PW, Deeks SG, Rodriguez B et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17: 19071915.
  • 21
    Florence E, Lundgren J, Dreezen C et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003; 4: 255262.
  • 22
    Ungsedhapand C, Srasuebkul P, Cardiello P. Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection. J Acquir Immune Defic Syndr 2004; 36: 693701.
  • 23
    Ananworanich J, Nuesch R, Teeratakulpisarn S et al. In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor-based versus non-protease inhibitor-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 32: 570572.
  • 24
    Ananworanich J, Moor Z, Siangphoe U et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005; 19: 185192.
  • 25
    Cardiello PG, Van Heeswijk RP, Hassink EA et al. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. J Acquir Immune Defic Syndr 2002; 29: 464470.
  • 26
    Cardiello PG, Hassink E, Ananworanich J et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005; 40: 594600.
  • 27
    Cardiello P, Srasuebkul P, Hassink E et al. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. HIV Med 2005; 6: 122128.
  • 28
    Nuesch R, Geigy N, Schaedler E, Battegay M et al. Effect of highly active antiretroviral therapy on hospitalization characteristics of HIV-infected patients. Eur J Clin Microbiol Infect Dis 2002; 21: 684687.
  • 29
    Nuesch R, Ananworanich J, Sirivichayakul S et al. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis 2005; 40: 728734.
  • 30
    Ruxrungtham K, Kroon ED, Ungsedhapand C et al. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients. AIDS 2000; 14: 13751382.
  • 31
    Ungsedhapand C, Kroon ED, Suwanagool S et al. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. J Acquir Immune Defic Syndr 2001; 27: 116123.
  • 32
    Boyd MA, Siangphoe U, Ruxrungtham K et al. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Med 2005; 6: 410420.
  • 33
    Duncombe C, Kerr SJ, Ruxrungtham K et al. HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. AIDS 2005; 19: 169178.
  • 34
    Castro KG, Ward JW, Slutske L. CDC revises HIV classification system, AIDS definition. W V Med J 1993; 89: 74.
  • 35
    Wit FW, Van Leeuwen R, Weverling GJ et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999; 179: 790798.
  • 36
    Grabar S, Le Moing V, Goujard C et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133: 401410.
  • 37
    Mocroft A, Ledergerber B, Viard JP et al. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA Study Group. J Infect Dis 2004; 190: 19471956.
  • 38
    Le Moing V, Chene G, Carrieri MP et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16: 2129.
  • 39
    Phillips AN, Pradier C, Lazzarin A et al. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001; 15: 23852395.
  • 40
    Paredes R, Mocroft A, Kirk O et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000; 160: 11231132.
  • 41
    Staszewski S, Miller V, Sabin C et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999; 13: 367373.
  • 42
    Paris D, Ledergerber B, Weber R et al. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses 1999; 15: 16311638.
  • 43
    Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998; 12: 21612167.
  • 44
    Deeks SG, Hecht FM, Swanson M et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13: F35F43.
  • 45
    Casado JL, Perez-Elias MJ, Antela A et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998; 12: F131F135.
  • 46
    Mocroft A, Phillips AN, Miller V et al. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. AIDS 2001; 15: 201209.
  • 47
    The AVANTI and INCAS Study Groups. Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit. AIDS 2000; 14: 13831388.
  • 48
    Grabar S, Pradier C, Corfec E et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000; 14: 141149.
  • 49
    Ledergerber B, Lundgren JD, Walker AS et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364: 5162.
  • 50
    Anastos K, Barron Y, Cohen MH et al. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004; 140: 256264.
  • 51
    Martin JC, Soriano V, Jimenez-Nacher I, Martinez P, Gonzalez-Lahoz J. Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies. Clin Microbiol Infect 2001; 7: 678681.
  • 52
    Moore AL, Kirk O, Johnson AM et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003; 32: 452461.
  • 53
    Moore AL, Sabin CA, Johnson MA, Phillips AN. Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Defic Syndr 2002; 29: 197202.
  • 54
    Nicastri E, Angeletti C, Palmisano L et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 2005; 19: 577583.
  • 55
    Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344: 720725.
  • 56
    Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000; 24: 475482.
  • 57
    Bureau of East Asian and Pacific Affairs. Background Note Thailand. http://state.gov/r/pa/ei/bgn/2814.htm 2005.